Skip to main content

Advertisement

SpringerLink
Log in

Educational Paper: Progression in chronic kidney disease and prevention strategies

  • Review
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) in children is a rare but devastating condition. Once a critical amount of nephron mass has been lost, progression of CKD is irreversible and results in end-stage renal disease (ESRD) and need of renal replacement therapy. The time course of childhood CKD is highly variable. While in children suffering from congenital anomalies of the kidneys and the urinary tract, progression of CKD in general is slow, in children with acquired glomerulopathies, disease progression can be accelerated resulting in ESRD within months. However, irrespective of the underlying kidney disease, hypertension and proteinuria are independent risk factors for progression. Thus, in order to prevent progression, the primary objective of treatment should always aim for efficient control of blood pressure and reduction of urinary protein excretion. Blockade of the renin–angiotensin–aldosterone system preserves kidney function not only by lowering blood pressure, but also by reducing proteinuria and exerting additional anti-proteinuric, anti-fibrotic, and anti-inflammatory effects. Besides, intensified blood pressure control, aiming for a target blood pressure below the 50th percentile, may exert additive renoprotective effects. Additionally, other modifiable risk factors, such as anemia, metabolic acidosis, dyslipidemia, and altered bone-mineral homeostasis may also contribute to CKD progression. In conclusion, beyond strict blood pressure control and reduction of urinary protein excretion, identification and treatment of both, renal disease-related and conventional risk factors are mandatory in children with CKD in order to prevent deterioration of kidney function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53

    Article  PubMed  CAS  Google Scholar 

  2. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qui P, Williams L, Batlle W (2005) Antiproteinuric effect of oral paracalcitol in chronic kidney disease. Kidney Int 68:2823–2828

    Article  PubMed  CAS  Google Scholar 

  3. Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, Procaccio M, Avolio L, Ciofani A, Dello Strologo L, Montini G (2004) Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Pediatr Nephrol 19:172–177

    Article  PubMed  Google Scholar 

  4. Ardissino G, Vigano S, Testa S, Dacco V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, la Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM, on behalf of the ItalKid Project (2007) No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - report from the ItalKid Project database. Nephrol Dial Transplant 22:2525–2530

    Article  PubMed  Google Scholar 

  5. Aydin Z, Duijs J, Bajerna IM, van Zonneveld AJ, Rabelink TJ (2007) Erythropoietin, progenitors, and repair. Kidney Int 72:516–520

    Article  Google Scholar 

  6. Bakris GL, Williams M, Dworkin L, Elliot WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646–661

    Article  PubMed  CAS  Google Scholar 

  7. Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3:486–492

    Article  PubMed  CAS  Google Scholar 

  8. Casas JP, Weiliang C, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033

    Article  PubMed  CAS  Google Scholar 

  9. Chaturvedi S, Jones C (2007) Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev 17:CD006863

    Google Scholar 

  10. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J (2004) The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140:167–174

    PubMed  Google Scholar 

  11. Chobanian AV, Barkis GL, Black DL, Cushman WC, Green LA, Izzo JLJ, Jones DW, Materson BJ, Oparil S, Wright JTJ, Roccella EJ (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2571

    Article  PubMed  CAS  Google Scholar 

  12. De Borst MH, Vervloet MG, ter Wee PM, Navis G (2011) Cross talk between the renin–angiotensin–aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 22:1603–1609

    Article  PubMed  Google Scholar 

  13. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084

    Article  PubMed  Google Scholar 

  14. Doulton TW, He FJ, MacGregor FA (2005) Systemic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:880–886

    Article  PubMed  CAS  Google Scholar 

  15. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, Investigators CREATE (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084

    Article  PubMed  Google Scholar 

  16. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE (2003) Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 143:89–97

    Article  PubMed  CAS  Google Scholar 

  17. Epstein M, Campese VM (2005) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45:2–14

    Article  PubMed  CAS  Google Scholar 

  18. European Medicines Agency (2012) http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/02/WC500122919.pdf

  19. Fassbinder W, Quarder O, Waltz A (1999) Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicenter randomized study. Int J Clin Pract 53:519–522

    PubMed  CAS  Google Scholar 

  20. Fouque D, Laville M (2009) Low-protein diets for chronic kidney disease in non diabetic adults. Cochrane database of systematic reviews, Issue 3, Art.No. CD001892. doi:10.1002/14651858.CD001892.pub3

  21. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC (2004) Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66:753–760

    Article  PubMed  Google Scholar 

  22. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Erich JHH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P, and Study Group Members of the Gesellschaft für Pädiatrische Nephrologie (GPN), Knebelmann B, Pirson Y, Grunfeld J-P, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Müller GA, Weber M (2012) Early angiotensin converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494–501

    Article  PubMed  CAS  Google Scholar 

  23. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mihnin F, Suo JM (1994) Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833–837

    Article  PubMed  CAS  Google Scholar 

  24. Iseki K, Ikemiya Y, Iseki C, Takishita S (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63:1468–1474

    Article  PubMed  Google Scholar 

  25. Iseki K, Kinjo K, Iseki C, Takishita S (2004) Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 44:806–814

    PubMed  CAS  Google Scholar 

  26. Jafar TH, Schmid CH, Landa M, Giatras J, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, DeJong P, DeZeeuw D, Lau J, Levey AS, for the ACE Inhibition in Progressive Renal Disease Study Group (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87

    PubMed  CAS  Google Scholar 

  27. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD study group (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-meta-analysis. Ann Intern Med 139:244–252

    PubMed  CAS  Google Scholar 

  28. Karamouzis I, Sarafidis PA, Karamouzis M, Illiadis S, Haidich A-M, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM (2008) Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 28:397–404

    Article  PubMed  CAS  Google Scholar 

  29. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J (1996) Blood pressure and end-stage renal disease in men. N Engl J Med 334:13–18

    Article  PubMed  CAS  Google Scholar 

  30. Klahr S, Levy AD, Beck GJ (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877–884

    Article  PubMed  CAS  Google Scholar 

  31. Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, Collins AJ, Kopple JD (2006) Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 48:876–888

    Article  Google Scholar 

  32. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P (2002) 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest 110:229–238

    PubMed  CAS  Google Scholar 

  33. Litwin M (2004) Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol 19:178–186

    Article  PubMed  Google Scholar 

  34. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A (1996) Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italien Cooperative Study Group. Nephrol Dial Transplant 11:461–467

    Article  PubMed  CAS  Google Scholar 

  35. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719–1742

    Article  PubMed  CAS  Google Scholar 

  36. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48:8–20

    Article  PubMed  CAS  Google Scholar 

  37. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of angiotensin-converting-enzme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945

    Article  PubMed  CAS  Google Scholar 

  38. Mulec H, Johnson SA, Bjorck S (1990) Relation between serum cholesterol and diabetic nephropathy. Lancet 335:1537–1538

    Article  PubMed  CAS  Google Scholar 

  39. Muntner P, Coresh J, Clinton Smith J, Eckfeldt J, Klag MJ (2000) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58:293–301

    Article  PubMed  CAS  Google Scholar 

  40. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576

    Article  Google Scholar 

  41. National Kidney Foundation (2003) K/DOQI Clinical practice guidelines for managing dyslipidemias in patients with kidney disease. Am J Kidney Dis 41:S1–S91 (Suppl 3)

    Google Scholar 

  42. National Kidney Foundation (2004) K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43:S1–S290 (Suppl 1)

    Google Scholar 

  43. National Kidney Foundation (2005) K/DOQI Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S12–S122 (Suppl 1)

    Google Scholar 

  44. Ogata H, Ritz E, Odoni G, Amann K, Orth SR (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959–967

    Article  PubMed  CAS  Google Scholar 

  45. Oh J, Beckmann J, Bloch J, Hettgen V, Mueller J, Li L, Hoemme M, Gross ML, Penzel R, Mundel P, Schaefer F, Schmitt CP (2011) Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int 80:483–492

    Article  PubMed  CAS  Google Scholar 

  46. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105

    Article  PubMed  Google Scholar 

  47. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleigth P, Anderson C (2008) Renal outcomes with telmisartan, ramipril, or both, in patients at high vascular risk (The ONTARGET Study): a multicenter, randomized, double-blind, controlled trial. N Engl J Med 358:1547–1559

    Article  PubMed  CAS  Google Scholar 

  48. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 370:221–229

    Article  PubMed  CAS  Google Scholar 

  49. Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175–1179

    Article  PubMed  CAS  Google Scholar 

  50. Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 297:1086–1091

    Article  PubMed  CAS  Google Scholar 

  51. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter LJ (1995) Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med 123:754–762

    PubMed  CAS  Google Scholar 

  52. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DSC (2007) Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72:549–556

    Article  PubMed  CAS  Google Scholar 

  53. Ruggenenti P, Perna A, Gherardi G, Garini G, Zocalli C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364

    Article  PubMed  CAS  Google Scholar 

  54. Ruggenenti P, Perna A, Remuzzi G (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63:2254–2261

    Article  PubMed  CAS  Google Scholar 

  55. Saland MJ, Ginsberg H, Fisher EA (2002) Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 14:197–204

    Article  PubMed  Google Scholar 

  56. Schaefer F, Mehls O (2004) Hypertension in chronic kidney disease. In: Portman RJ, Sorof JM, Ingelfinger JR (eds) Pediatric hypertension. Humana Press, Totowa, pp 371–387

    Google Scholar 

  57. Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097

    Article  PubMed  Google Scholar 

  58. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Shaeff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115–2124

    Article  PubMed  CAS  Google Scholar 

  59. Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59

    Article  PubMed  CAS  Google Scholar 

  60. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC (2006) Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47:715–726

    Article  PubMed  CAS  Google Scholar 

  61. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576–579

    Article  PubMed  CAS  Google Scholar 

  62. Tarver-Carr M, Brancati F, Eberhardt M, Powe N (2000) Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol 11:168A

    Google Scholar 

  63. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephroptahy. Lancet 349:1857–1863

    Article  Google Scholar 

  64. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007) 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105–1187

    Google Scholar 

  65. Van Dyck M, Proesmans W (2004) Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 19:688–690

    Article  PubMed  Google Scholar 

  66. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D (1997) Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63:S58–S62

    PubMed  Google Scholar 

  67. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Study Group for Growth Hormone Treatment in Chronic Renal Failure (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248

    Article  PubMed  CAS  Google Scholar 

  68. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W (2003) Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. [Abstract]. Am J Cardiol 92:38–42

    Article  PubMed  CAS  Google Scholar 

  69. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 349:1117–1123

    Article  PubMed  CAS  Google Scholar 

  70. Wolf M (2012) Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int, May 23 [Epub ahead of print]

  71. Wong C, Kanetsky P, Raj D (2008) Genetic polymorphisms of the RAS-cytokine pathway and chronic kidney disease. Pediatr Nephrol 23:1037–1051

    Article  PubMed  Google Scholar 

  72. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG (2003) African American study of kidney disease and hypertension: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421–2431

    Article  Google Scholar 

  73. Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen A-M, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood pressure control and renal failure progression in children. The ESCAPE Trial Group. N Engl J Med 361:1639–1650

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University of Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany

    Betti Schaefer & Elke Wühl

Authors
  1. Betti Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elke Wühl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elke Wühl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schaefer, B., Wühl, E. Educational Paper: Progression in chronic kidney disease and prevention strategies. Eur J Pediatr 171, 1579–1588 (2012). https://doi.org/10.1007/s00431-012-1814-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-012-1814-5

Keywords

Search

Navigation